Business
Block Listing Application
Shield Therapeutics plc has applied to the London Stock Exchange for a block listing of 15,000,000 ordinary shares of 1.5 pence each, expected to be admitted to trading on December 23, 2025. These shares are intended for allocation to the Shield Therapeutics Retention and Performance Share Plan. Disclaimer*
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n\nShield Therapeutics plc\n(\"Shield\" or the \"Company\" or the \"Group\")\n \nBlock Listing Application\n \nLondon, UK, 18 December 2025: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency, has today made an application to the London Stock Exchange for a block listing of 15,000,000 ordinary shares of 1.5 pence each in the Company (\"Block Listing Shares\") to be admitted to trading on the London Stock Exchange (\"Admission\") and to be allocated to the schemes listed below.\n \nThe 15,000,000 Block Listing Shares are to be issued under the following schemes:\n \n· Shield Therapeutics Retention and Performance Share Plan\n \nAdmission is expected to occur on 23 December 2025.\n \nFor further information please contact:\n \n\n\n\n\nShield Therapeutics plc\n\n\nwww.shieldtherapeutics.com\n\n\n\n\nAnders Lundstrom, CEO\nSantosh Shanbhag, CFO\nLucy Huntington-Bailey, Company Secretary\n\n\n+44 (0) 191 511 8500\[email protected]\n\n\n\n\n \nNominated Adviser and Joint Broker\n\n\n\n\n\n\n\nPeel Hunt LLP\n\n\n\n\n\n\n\nJames Steel/Christopher Golden\n\n\n+44 (0)20 7418 8900\n\n\n\n\n\n\n\n\n\n\n\n\nJoint Broker\nCavendish Ltd\nGeoff Nash/ Isaac Hooper/Nigel Birks/Harriet Ward \n\n\n \n \n \n+44 (0)20 7220 0500\n\n\n\n\n \n \nAbout Iron Deficiency and ACCRUFeR®/FeRACCRU®\nClinically low iron levels (aka iron deficiency, ID) can cause serious health problems for adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the #1 branded prescription oral iron the market today (*data source - IQVIA Xponent PlanTrak).\n \nACCRUFeR®/FeRACCRU® (ferric maltol) is a novel, stable, non-salt-based oral therapy for adults with ID/IDA. The drug has a n...